You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR GUSELKUMAB


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for guselkumab

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01866007 ↗ A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants Completed Janssen Research & Development, LLC Phase 1 2013-05-09 The purpose of this study is to evaluate the pharmacokinetic (what the body does to the medication) comparability of guselkumab in lyophilized and liquid formulations. Also to evaluate pharmacokinetic comparability of liquid formulation of guselkumab when delivered as prefilled syringe with UltraSafe Passive Delivery System [PFS-U] or with a prefilled syringe facilitated injection device [PFS FID]) following a single subcutaneous (SC) administration of 100 mg guselkumab in healthy participants.
NCT02155192 ↗ An Exploratory Genetic Study in Participants With Psoriasis Completed Janssen Research & Development, LLC 2014-03-01 The purpose of this study is to evaluate the association between genetic factors and response to treatment (guselkumab, ustekinumab, adalimumab, or etanercept) and psoriasis (scaly skin rash).
NCT02203032 ↗ A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab Completed Janssen Research & Development, LLC Phase 3 2014-10-07 The purpose of this study is to evaluate the efficacy and safety of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash) who had inadequate response to ustekinumab.
NCT02207231 ↗ A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis Completed Janssen Research & Development, LLC Phase 3 2014-11-26 The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis.
NCT02207244 ↗ A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment Completed Janssen Research & Development, LLC Phase 3 2014-11-03 The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash).
NCT02319759 ↗ Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA) Completed Janssen Research & Development, LLC Phase 2 2015-03-27 The purpose of this study is to evaluate the efficacy, safety and tolerability of guselkumab in participants with Active Psoriatic Arthritis (PsA).
NCT02325219 ↗ An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis Completed Janssen Pharmaceutical K.K. Phase 3 2014-12-19 The purpose of this study is to demonstrate the superiority of CNTO 1959 (guselkumab) to placebo in the treatment of participants with moderate to severe plaque-type psoriasis (A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for guselkumab

Condition Name

Condition Name for guselkumab
Intervention Trials
Psoriasis 17
Arthritis, Psoriatic 8
Healthy 7
Psoriatic Arthritis 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for guselkumab
Intervention Trials
Psoriasis 24
Arthritis, Psoriatic 12
Arthritis 12
Crohn Disease 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for guselkumab

Trials by Country

Trials by Country for guselkumab
Location Trials
United States 443
Canada 80
Germany 28
Poland 25
Spain 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for guselkumab
Location Trials
Texas 27
California 25
Florida 24
New York 21
Ohio 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for guselkumab

Clinical Trial Phase

Clinical Trial Phase for guselkumab
Clinical Trial Phase Trials
Phase 4 10
Phase 3 25
Phase 2/Phase 3 3
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for guselkumab
Clinical Trial Phase Trials
Completed 22
Recruiting 21
Not yet recruiting 13
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for guselkumab

Sponsor Name

Sponsor Name for guselkumab
Sponsor Trials
Janssen Research & Development, LLC 36
Janssen Pharmaceutical K.K. 6
Janssen Scientific Affairs, LLC 4
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for guselkumab
Sponsor Trials
Industry 60
Other 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.